DexCom price target raised to $105 from $85 at Canaccord. Canaccord analyst Kyle Rose raised his price target on DexCom to $105 from $85 following the ADA meeting and ahead of what he expects will be a strong Q2 supported by underlying market strength across CGM, the early contribution of G6, and limited disruption from competitive entrants. Rose reiterated his Buy rating on DexCom shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.